spironolactone has been researched along with Cancer of Prostate in 20 studies
Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827)
spironolactone : A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Spironolactone is an aldosterone antagonist used for managing chronic heart failure (HF) with known antiandrogenic effects." | 8.02 | Impact of spironolactone exposure on prostate cancer incidence amongst men with heart failure: A Pharmacoepidemiological study. ( Feldman, RD; Hiebert, BM; Janzen, BW; Kim, JO; Ong, AD; Sanjanwala, RM, 2021) |
| "While originally approved for the management of heart failure, hypertension, and edema, spironolactone is commonly used off label in the management of acne, hidradenitis, androgenetic alopecia, and hirsutism." | 5.22 | Association of Spironolactone Use With Risk of Cancer: A Systematic Review and Meta-analysis. ( Barbieri, JS; Bommareddy, K; Hamade, H; Lopez-Olivo, MA; Tosh, T; Wehner, M, 2022) |
| " Spironolactone is an aldosterone antagonist used for managing chronic heart failure (HF) with known antiandrogenic effects." | 4.02 | Impact of spironolactone exposure on prostate cancer incidence amongst men with heart failure: A Pharmacoepidemiological study. ( Feldman, RD; Hiebert, BM; Janzen, BW; Kim, JO; Ong, AD; Sanjanwala, RM, 2021) |
| "The spironolactone is a diuretic of potassium savings." | 1.36 | [PSA and spironolactone]. ( Coulange, C; Delaporte, V; Deturmeny, J; Lechevallier, E; Maurin, C; Rybikowski, S, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (40.00) | 18.7374 |
| 1990's | 3 (15.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (25.00) | 24.3611 |
| 2020's | 4 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, C | 1 |
| Chai, X | 1 |
| Hu, X | 1 |
| Lou, S | 1 |
| Li, D | 1 |
| Hou, T | 1 |
| Cui, S | 1 |
| Bommareddy, K | 1 |
| Hamade, H | 1 |
| Lopez-Olivo, MA | 1 |
| Wehner, M | 1 |
| Tosh, T | 1 |
| Barbieri, JS | 1 |
| Beckmann, K | 1 |
| Garmo, H | 1 |
| Lindahl, B | 1 |
| Holmberg, L | 1 |
| Stattin, P | 1 |
| Adolfsson, J | 1 |
| Cruickshank, JK | 1 |
| Van Hemelrijck, M | 1 |
| Hiebert, BM | 1 |
| Janzen, BW | 1 |
| Sanjanwala, RM | 1 |
| Ong, AD | 1 |
| Feldman, RD | 1 |
| Kim, JO | 1 |
| End, D | 1 |
| Molina, A | 1 |
| Todd, M | 1 |
| Meyers, ML | 1 |
| Chuang, YW | 1 |
| Yu, MC | 1 |
| Huang, ST | 1 |
| Yang, CK | 1 |
| Chen, CH | 1 |
| Lo, YC | 1 |
| Lin, CL | 1 |
| Shu, KH | 1 |
| Yu, TM | 1 |
| Kao, CH | 1 |
| Rybikowski, S | 1 |
| Maurin, C | 1 |
| Deturmeny, J | 1 |
| Delaporte, V | 1 |
| Lechevallier, E | 1 |
| Coulange, C | 1 |
| Richards, J | 1 |
| Lim, AC | 1 |
| Hay, CW | 1 |
| Taylor, AE | 1 |
| Wingate, A | 1 |
| Nowakowska, K | 1 |
| Pezaro, C | 1 |
| Carreira, S | 1 |
| Goodall, J | 1 |
| Arlt, W | 1 |
| McEwan, IJ | 1 |
| de Bono, JS | 1 |
| Attard, G | 1 |
| Sundar, S | 1 |
| Dickinson, PD | 1 |
| Bare, RL | 1 |
| Torti, FM | 1 |
| Walsh, PC | 1 |
| Siiteri, PK | 1 |
| Baba, S | 2 |
| Murai, M | 1 |
| Jitsukawa, S | 1 |
| Hata, M | 1 |
| Tazaki, H | 1 |
| Huben, RP | 1 |
| Sciarra, F | 1 |
| Toscano, V | 1 |
| Concolino, G | 1 |
| Di Silverio, F | 1 |
| Labrie, C | 1 |
| Cusan, L | 1 |
| Plante, M | 1 |
| Lapointe, S | 1 |
| Labrie, F | 1 |
| Namer, M | 1 |
| Sogani, PC | 1 |
| Fair, WR | 1 |
| Newmark, SR | 1 |
| Dluhy, RG | 1 |
| Bennett, AH | 1 |
| Rothauge, CF | 1 |
| Breitwieser, P | 1 |
| Wildberger, JE | 1 |
4 reviews available for spironolactone and Cancer of Prostate
| Article | Year |
|---|---|
Association of Spironolactone Use With Risk of Cancer: A Systematic Review and Meta-analysis.
Topics: Acne Vulgaris; Aged; Breast Neoplasms; Female; Hirsutism; Humans; Male; Middle Aged; Prostatic Neopl | 2022 |
Endocrine therapy of prostate cancer.
Topics: 5-alpha Reductase Inhibitors; Adenocarcinoma; Aminoglutethimide; Androgen Antagonists; Antineoplasti | 1998 |
Clinical applications of antiandrogens.
Topics: Androgen Antagonists; Breast Neoplasms; Cyproterone; Cyproterone Acetate; Female; Flutamide; Humans; | 1988 |
Treatment of advanced prostatic cancer.
Topics: Adrenalectomy; Aminoglutethimide; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protoco | 1987 |
3 trials available for spironolactone and Cancer of Prostate
| Article | Year |
|---|---|
Hormone therapy of prostatic bone metastases.
Topics: Actuarial Analysis; Androgen Antagonists; Bone Neoplasms; Combined Modality Therapy; Diethylstilbest | 1992 |
Antiandrogens: clinical applications.
Topics: Acne Vulgaris; Adult; Androgen Antagonists; Cyproterone; Cyproterone Acetate; Dermatitis, Seborrheic | 1990 |
Treatment of advanced prostatic cancer.
Topics: Adrenalectomy; Aminoglutethimide; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protoco | 1987 |
14 other studies available for spironolactone and Cancer of Prostate
| Article | Year |
|---|---|
Discovery of 2-(1-(3-Chloro-4-cyanophenyl)-1
Topics: Acetamides; Androgen Antagonists; Androgen Receptor Antagonists; Cell Line, Tumor; Cell Proliferatio | 2022 |
Spironolactone use is associated with lower prostate cancer risk: a population-wide case-control study.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Case-Control Studies; Drug Prescriptions; Humans; Kal | 2020 |
Impact of spironolactone exposure on prostate cancer incidence amongst men with heart failure: A Pharmacoepidemiological study.
Topics: Aged; Aged, 80 and over; Heart Failure; Humans; Incidence; Male; Middle Aged; Mineralocorticoid Rece | 2021 |
Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100.
Topics: Androstenols; Humans; Male; Phenylthiohydantoin; Prednisolone; Prostatic Neoplasms; Receptors, Andro | 2013 |
Spironolactone and the risk of urinary tract cancer in patients with hypertension: a nationwide population-based retrospective case-control study.
Topics: Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; | 2017 |
[PSA and spironolactone].
Topics: Aged; Androgen Antagonists; Humans; Male; Neoplasm Recurrence, Local; Prostate-Specific Antigen; Pro | 2010 |
Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100.
Topics: Androgen Receptor Antagonists; Androgens; Androstenes; Androstenols; Anilides; Benzamides; Binding, | 2012 |
Spironolactone, a possible selective androgen receptor modulator, should be used with caution in patients with metastatic carcinoma of the prostate.
Topics: Adenocarcinoma; Aged, 80 and over; Contraindications; Heart Failure; Humans; Male; Prostate-Specific | 2012 |
Suppression of plasma androgens by spironolactone in castrated men with carcinoma of the prostate.
Topics: Aged; Androgens; Androstenedione; Castration; Dehydroepiandrosterone; Depression, Chemical; Humans; | 1975 |
[Antiandrogenic effect of spironolactone. II. Morphological studies of the prostate using point volumetry (author's transl)].
Topics: Aged; Animals; Biometry; Dogs; Humans; Male; Middle Aged; Prostate; Prostatic Neoplasms; Spironolact | 1977 |
Antiandrogenic effects of spironolactone: hormonal and ultrastructural studies in dogs and men.
Topics: Adrenal Glands; Androgen Antagonists; Androgens; Animals; Cytoplasm; Dogs; Humans; Leydig Cells; Mal | 1978 |
Analysis of the androgenic activity of synthetic "progestins" currently used for the treatment of prostate cancer.
Topics: Adrenal Glands; Animals; Chlormadinone Acetate; Cyproterone; Cyproterone Acetate; Dihydrotestosteron | 1987 |
Ectopic adrenocorticotropin syndrome with prostatic carcinoma.
Topics: 17-Hydroxycorticosteroids; 17-Ketosteroids; Adenocarcinoma; Adrenocorticotropic Hormone; Blood Gluco | 1973 |
[Hormone therapy of prostatic carcinoma].
Topics: Adult; Aged; Castration; Estrogens; Hormones; Humans; Imides; Male; Middle Aged; Pituitary Irradiati | 1971 |